a public good project by the
Synthesis
Company
of California

© 2026

Yan Kong | doi.page

0 works0 citations0 h-index

Yan Kong

Qingdao University(CN)Affiliated Hospital of Qingdao University(CN)

Publications by Year

Research Areas

Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses

Most-Cited Works

→ Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
→ Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets(2019)326 cited
→ Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma(2013)197 cited
→ Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients(2019)186 cited
→ Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients(2018)186 cited
→ Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial(2019)165 cited

→ The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients(2016)161 cited

→ Coupling of mitochondrial function and skeletal muscle fiber type by a miR‐499/Fnip1/ AMPK circuit(2016)124 cited

→ Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy(2017)115 cited

→ Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma(2021)112 cited